Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 0.48 |
| ▸ | MTOR | P42345 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.45 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.42 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6881791 | 0.81 | TGFBR1 (0.67) | TGFBR1MTORMAPK14 | |
| SCHEMBL6757465 | 0.78 | TGFBR1 (0.74) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL4476934 | 0.78 | TGFBR1 (0.49) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL6760976 | 0.77 | TGFBR1 (0.54) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL4481445 | 0.76 | TGFBR1 (0.53) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL6076066 | 0.76 | TGFBR1 (0.47) | TGFBR1MTORMAPK14 | |
| SCHEMBL6759976 | 0.71 | TGFBR1 (0.51) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL30585318 | 0.70 | TGFBR1 (0.73) | TGFBR1MAPK14KDRTGFBR2 | |
| SCHEMBL26664542 | 0.70 | TGFBR1 (0.73) | TGFBR1MAPK14KDRTGFBR2 | |
| SCHEMBL6762343 | 0.69 | TGFBR1 (0.70) | TGFBR1MTORMAPK14RIPK2ACVR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220230-A1 | Pyridinylimidazoles | SMITHKLINE BEECHAM P.L.C. | 2004-11-04 | — | — | US | disclosed |
| US-20030166633-A1 | Pyridinylimidazoles | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-09-04 | — | — | US | disclosed |
| EP-1257543-A1 | PYRIDINYLIMIDAZOLES | SMITHKLINE BEECHAM PLC (GB) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001062756-A1 | PYRIDINYLIMIDAZOLES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166633-A1 | Pyridinylimidazoles | NR0B1, NR1I2, NR0B2 | TGFBR1 431/4885MTOR 3903/4885MAPK14 3277/4885 |
| US-20040220230-A1 | Pyridinylimidazoles | NR0B1, NR1I2, NR0B2 | TGFBR1 485/4885MTOR 4099/4885MAPK14 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.